OccuRx to highlight inflammation and fibrosis strategies while attending 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Melbourne, Australia, 07 January 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.

OccuRx and its management team including Chief Executive Officer, Professor Darren Kelly will attend 37th Annual J.P. Morgan Health Conference in San Francisco. The OccuRx team will highlight their scientific advancements in anti-inflammatory and anti-fibrotic therapies, including their clinical development progress and plans with its novel therapeutic platform.

The conference will take place on 7th – 10th  January, 2019 in San Francisco, California and is one of the largest and most informative healthcare investment symposiums in the industry.

OccuRx are progressing their drug development program for its novel therapeutic platform of precision therapies for the treatment of diabetic complications associated with fibrosis, including diabetic chronic kidney disease, diabetic retinopathy, wet age-related macular degeneration (AMD).

The company’s most advanced drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.

Diabetes continues to be a major public health problem and has many serious complications that affect multiple organs of the body particularly the eye, kidneys and blood vessels. Over time damage to blood vessels of the eyes and filtering units in the kidneys occurs, leading to chronic inflammation, microvascular changes and irreversible fibrosis. This is associated with significant morbidity and/or mortality including end stage kidney disease and, in the eye, diabetic retinopathy and blindness. With no cure available, intensive research is required to develop novel treatment possibilities for these diabetic complications.

There are currently no treatments available for kidney fibrosis, which presents in the majority of chronic kidney disease (CKD) patients. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs. OccuRx is using genetic analysis to identify the most suitable patients for treatment.

During the J.P. Morgan Health Conference, more than 450 companies, both public and private, deliver presentations to more than 10,000 attendees. It provides a unique platform for investors and industry leaders in the biotech and pharmaceutical sector.